BridgeMD
Effect of Camostat for Kidney Protection in Chronic Kidney Disease (CamKid).
EU CTIS ID: 2023-508516-34-00
What this study is testing
The main objective is to evaluate the effect of Camostat mesilate on salt and water excretion including total body water content and blood pressure in patients with chronic kidney disease compared to healthy controls.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age>18 years.
- A clinical diagnosis of CKD of any course and meet the following criteria at screening: a. eGFR > 30 ml/min/1.73m2 b. U-ACR > 300 mg/g.
- Stable antihypertensive treatment 2 weeks before start of investigated medical drug (IMP) and maintain this treatment throughout the study.
- Office blood pressure at the screening session should be >120/70 mmHg and <150/90 mmHg.
- Capable of providing a signed informed consent and comply with study requirements.
- Women with childbearing potential must have a negative pregnancy test (urine hCG) at spot urine at the screening visit and should use contraception during the study and until one week after completion of study treatment.
You likely can't join if
- Treatment with Amiloride, Spironolactone, Aldosterone, or analogues.
- Breastfeeding.
- Congestive heart failure NYHA class IV, unstable or acute congestive heart failure.
- Recent cardiovascular events < 2 months prior to screening: a. Coronary artery revascularization. b. Acute stroke or TIA. c. Acute coronary syndrome.
- Allergy or hypersensitivity to the IMP.
- Addison’s disease.
See the full eligibility criteria
- Age>18 years.
- A clinical diagnosis of CKD of any course and meet the following criteria at screening: a. eGFR > 30 ml/min/1.73m2 b. U-ACR > 300 mg/g.
- Stable antihypertensive treatment 2 weeks before start of investigated medical drug (IMP) and maintain this treatment throughout the study.
- Office blood pressure at the screening session should be >120/70 mmHg and <150/90 mmHg.
- Capable of providing a signed informed consent and comply with study requirements.
- Women with childbearing potential must have a negative pregnancy test (urine hCG) at spot urine at the screening visit and should use contraception during the study and until one week after completion of study treatment.
- Treatment with Amiloride, Spironolactone, Aldosterone, or analogues.
- Breastfeeding.
- Congestive heart failure NYHA class IV, unstable or acute congestive heart failure.
- Recent cardiovascular events < 2 months prior to screening: a. Coronary artery revascularization. b. Acute stroke or TIA. c. Acute coronary syndrome.
- Allergy or hypersensitivity to the IMP.
- Addison’s disease.
- Gastric bypass operation.
- Lactose intolerance since lactose serves as one of the inactive ingredients in the IMP.
- Participation in other clinical trials within the last 30 days.
- Treatment with NSAIDs.
- Hyperkalemia > 5.0 mmol/L at screening.
- P-bilirubin > 25 umol/L at screening.
- Ongoing cancer treatment.
- Treatment with immunosuppressive therapy within 6 months prior to screening.
- History of organ transplantation.
- Evidence of current infection (CRP>50 or temperature > 38 C).
- Severe hepatic insufficiency classified as Child-Pugh C.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.